Newer developments in idiopathic pulmonary fibrosis in the era of anti-fibrotic medications.
Idiopathic pulmonary fibrosis (IPF) is the most common interstitial lung disease with a fatal prognosis. Over the last decade, the concepts in pathobiology of pulmonary fibrosis have shifted from a model of chronic inﬂammation to dysregulated ﬁbroproliferative repair in genetically predisposed patients. Although new breakthrough treatments are now available that slow the progression of the disease, several newer anti-inflammatory and anti-fibrotic drugs are under investigation. Patients with IPF often have coexistent conditions; prompt detection and interventions of which may improve the overall outcome of patients with IPF. Here, we summarize the present understanding of pathogenesis of IPF and treatment options for IPF in the current landscape of new anti-fibrotic treatment options.
a Division of Pulmonary & Critical Care Medicine , Winthrop-University Hospital , Mineola , NY , USA.|b Department of Medicine , SUNY Stony Brook School of Medicine , NY , USA.
Girish B
GB
Nair
a Division of Pulmonary & Critical Care Medicine , Winthrop-University Hospital , Mineola , NY , USA.
Ajsza
A
Matela
a Division of Pulmonary & Critical Care Medicine , Winthrop-University Hospital , Mineola , NY , USA.
Daniel
D
Kurbanov
c Department of Medicine & Lab Medicine (Adjunct), Division of Pulmonary & Critical Care Medicine , University of Washington , Seattle , WA , USA.
Ganesh
G
Raghu
D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D006801:Humans; D054990:Idiopathic Pulmonary Fibrosis / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology
D000893:Anti-Inflammatory Agents
Idiopathic pulmonary fibrosis; Pulmonary fibrosis; nintedanib; novel targets; pirfenidone